Health Headlines: From Ebola Breakthroughs to Global Drug Deals

The U.S. FDA investigates anesthesia complications in patients with Venezuelan ancestry. AstraZeneca partners with CSPC for kidney disease drugs. Trials for Bundibugyo Ebola treatment begin in DRC. The U.S. provisional mortality rate drops, but flu deaths rise. Tanzania receives U.S. health investment. Celea advances lung disease drug trials.

The U.S. Food and Drug Administration (FDA) announced an investigation into severe neurological complications linked to anesthesia in patients of Venezuelan ancestry. This inquiry highlights concerns over the safety of general anesthetics like sevoflurane.

AstraZeneca has signed a significant deal with China's CSPC Pharmaceutical Group valued at $1.77 billion to develop potentially groundbreaking medicines for kidney disease treatment. However, the specific diseases targeted remain unspecified.

A milestone was reached in the Democratic Republic of Congo as the first patient was enrolled in a trial for treating the Bundibugyo Ebola outbreak. Despite progress, challenges remain, including an attack on an Ebola treatment center, causing fatalities and illustrating ongoing difficulties.